Irodalom:
1. Berger AC, Watson JC, Ross EA, Hoffmann JP.: The metastatic/examined lymph node ratio is an important
prognostic factor after pancreatinoduodenectomy for pancreatic adenocarcinoma. Am Surg 70:2354-240, 2004
2. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V.: Prognostic and therapeutic significance
of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70:255-264, 2006
3. Cao D, Antonescu C, Wong G, Winter J, Maitra A, Adsay NV, Klimstra DS, Hruban RH.: Positive
immunohistochemical staining of KIT in solid-pseudopapillay neoplasms of the pancreas is not associated
with KIT/PDGFRA mutations. Mod Pathol 19:1157-1163, 2006
4. Chung GG, Yoon HH, Zerkowski MP, Ghosh S, Thomas L, Harigopal M, Charette LA, Salem RR, Camp RL,
Rimm DL, Burtness BA.: Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic
cancer tissue microarray. Cancer 106:1677-1684, 2006
5. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B,
Gallinger S.: Prognostic factors in resected pancreatic adenocarcinoma: analysis off actual 5-yar survivors.
J Am Coll Surg 198:722-731, 2004
6. Dang C, Zhang Y, Ma Q, Shimahara Y.: Expression of nerve growth factor receptors is correlated with
progression and prognosis of human pancreatic cancer. Gastroenterol Hepatol 21:850-858, 2006
458 Gastro Update 2007
7. Duffy JP, Eibl G, Reber HA, Hines OJ.: Influence of hypoxia and neoangiogenesis on the growth of
pancreatic cancer. Molec Cancer 2:1-12, 2003
8. Einama T, Kagata Y, Tsuda H, Morita D, Ogata S, Ueda S, Takigawa T, Kawarabayashi N, Fukatsu K,
Sugiura Y, Matsubara O, Hatsuse K.: High-level Skp2 expression in pancreatic ductal adenocarcinoma:
correlation with the extent of lymph node metastasis, higher histological grade, and poorer patients outcome.
Pancreas 32:376-381, 2006
9. Fukumoto A, Ikeda N, Sho M, Tomoda K, Kanehiro H, Hisanaga M, Tsurui Y, Tsutsumi M, Kato JY,
Nakajima Y.: Prognostic significance of localized p27Kip1 and potential role of Jab1/CSN5 in pancreatic
cancer. Oncol Rep 11:277-284, 2004
10. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M,
Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H.: CD8+ tumor-infiltrating
lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.
Pancreas 28:e26-31, 2004
11. Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D,
Del Chi8aro M, Iannopollo M, Bevilacqua G, Mosca F, Danesi R.: Transcription analysis of human
equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Cancer Res 66:3928-3935, 2006
12. Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D,
Koch R, Kalthoff H, Schackert HD, Seager HD, Klöppel G, Pilarsky C.: ADAM9 expression in pancreatic
cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer
90:1053-1058, 2004
13. Hiraoka N, Onozato K, Kosuge T, Hirohashi S.: Prevalence of FOXP3+ regulatory T cells increases
during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer
Res 12:5423-5434, 2006
14. Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M.: Clinical significance of
aminopeptide N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res 9:1503-1508, 2003
15. Immervoll H, Hoem D, Kugarajh K, Steine SJ, Molven A.: Molecular analysis of the EGFR-RAS-RAF
pathway in pancreatic ductal adenocarcinomas: lack of mutation in the BRAF and EGFR genes.
Virchows Arch 448:788-796, 2006
16. Jiang XT, Tao HQ, Zou SC.: Detection of serum tumor markers in the diagnosis and treatment of
patients with pancreatic cancer. Hepatobiliary Pancreatic Dis Inst 3:363-468, 2004
17. Jinfeng M, Kimura W, Hirai I, Sakurai F, Moriya T, Mizutani M.: Expression off MUC5AC and MUC6 in
invasive ductal carcinoma of the pancreas and relationship with prognosis. Int J Gastrointest Cancer 34:9-18, 2003
18. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C.: Cyclooxygenase-2 expression correlates with
poor prognosis in pancreatic cancer. J Clin Pathol 59:382-386, 2006
19. Juuti A, Nordling S, Louhimo J, Lundin J, von Boguslawski K, Haglund C.: Loss of p27 expression is
associated with poor prognosis in stag I-II pancreatic cancer. Oncology 65:371-377, 2003
20. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Fujimoto K, Wada M, Miyatake S, Imamura M.:
Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136:443-448, 2004
21. Keleg S, Büchler P, Ludwig R, Büchler MW, Friess H.: Invasion and metastasis in pancreatic cancer.
Molec Cancer 2:1-14, 2003
22. Kitada T, Seki S, Sakaguchi H, Sawada T, Hirakawa K, Wakasa K.: Clinicopathological significance of
hypoxia-inducible factor-1a expression in human pancreatic carcinoma. Histopathol 43:550-555, 2003
23. Krishnan S, Rana V, Janjan NA, Abbruzzese JL, Gould MS, Das P, Delclos ME, Palla S, Guha S,
Varadhachary G, Evans DB, Wolff RA, Crane CH.: Prognostic factors in patients with unresectable
locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer 107:2589-2596, 2006
24. Kristiansen G, Jacob J, Buckendahl AC, Grutzmann R, Alldinger I, Sipos B, Kloppel G, Bahra M,
Langrehr JM, Neuhaus P, Dietel M, Pilarsky C.: Peroxisome proliferators-activated receptor gamma is
Genetika 459
highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer
Res 12:6444-6451, 2006
25. Kuwahara K, Sasaki T, Kuwada Y, Murakami M, Yamasaki S, Chayama K.: Expression of angiogenic
factors in pancreatic ductal carcinoma: a correlative study with Clinicopathologic parameters and
patient survival. Pancreas 26:344-349, 2003
26. Laurell H, Bouisson M, Berthelemy P, Rochaix P, Dejean S, Besse P, Susini C, Pradayrol L, Vaysse N,
Buscail L.: Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling
and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration
samples. World J Gastroenterol 12:3344-3351, 2006
27. Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL.: Singe nucleotide polymorhisms
of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin
Oncol 24:1720-1728, 2006
28. Li D, Liu H, Chang DZ, Beinart G, Wolff RA, Evans DB, Hassan MM, Abbruzzese JL.: Significant
effect of homologues recombination DNA repair gene polymorphisms on pancreatic cancer survival.
Cancer Res 66:3323-3330, 2006
29. Li YJ, Meng YX, Ji XR.: Relationship between expression of E-cadherin and alpha-catenin and biological
behaviors of human pancreatic cancer. Hepatobiliary Pancreat Dis Int 2:471-477, 2003
30. Liu B, Lu KY.: Neural invasion in pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 1:469-476, 2002
31. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF,
Bast RC Jr.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal
cancer. J Clin Oncol 24: 1-15 , 2006
32. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Hanash S.:
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identified multiple genes
differentially regulated in pancreatic cancer. Cancer Res 63:2649-2657, 2003
33. Louhimo J, Alfthan H, Stenman UH, Haglund C.: Serum HCG beta and CA 72-4 are stronger prognostic
factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 66:126-131, 2004
34. Nakahashi C, Oda T, Kinoshita T, Ueda T, Konishi M, Nakagohri T, Inoue K, Furuse J, Ochiai A,
Ohkohchi N.: The important of liver metastasis on mortality in patients initially diagnosed with locally
advanced or resectable pancreatic cancer. Int J Gastrointest Cancer 33:155-164, 2003
35. Oida Y, Yamazaki H, Tobita K, Mukai M, Ohtani Y, Miyazaki N, Abe Y, Imaizumi T, Makuuchi H,
Ueyama Y, Nakamura M.: Increased S100A4 expression combined with decreased E-cadherin expression
predicts a poor outcome of patients with pancreatic cancer. Oncol Rep 16:457-463, 2006
36. Ryu B, Jones J, Hollingsworth MA, Hruban RH, Kern SE.: Invasion-specific genes in malignancy: serial
analysis of gene expression comparisons of primary and passaged cancer. Anticancer Res 61:1833-1838, 2001
37. Saidi RF, Williams F, Silberberg B, Mittal VK, ReMine SG, Jacobs MJ.: Expression of interferon receptors
in pancreatic cancer: identification of a novel prognostic factor. Surgery 139:743-748, 2006
38. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ.: Incidence, mechanism and prognostic
value of activated AKT in pancreas cancer. Br J Cancer 89:2110-2115, 2003
39. Schwarz RE, Smith DD.: Extent of lymph node retrieval and pancreatic cancer survival: information
from a large US population database. Ann Surg Oncol 13:1189-1200, 2006
40. Sierzega M, Popiela T, Kulig J, Nowak K.: The ratio of metastatic/resected lymph node is an independent
prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 33:240-245, 2006
41. Skalicky DA, Kench JG, Segara D, Coleman MJ, Sutherland RL, Henshall SM, Musgrove EA, Biankin AV.:
Cyclin E expression and outcome in pancreatic ductal adenocarcinomas. Cancer Epidemiol Biomarkers
Prev 15:1941-1947, 2006
42. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, Wiebke EA.: Analysis of
Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas.
Am J Surg 186:486-492, 2003
460 Gastro Update 2007
43. Suzuki K, Aiura K, Kitagou M, Hoshimoto S, Takahashi S, Ueda M, Kitajima M.: Platelets counts closely
correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology
51:847-853, 2004
44. Talar-Wojnarowska R, Malecka-Panas E.: Molecular pathogenesis of pancreatic adenocarcinomas:
potential clinical implications. Med Sci Monit 12:RA186-193, 2006
45. Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, Einama T, Morita D, Fukatsu K,
Sugiura Y, Matsubara O, Mochizuki H.: Potential crosstalk between insulin-like growth factor receptor
type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod
Pathol 19:788-796, 2006
46. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K,
Mochizuki H.: The correlation between cytoplasmic overexpression of epidermal growth factor receptor
and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas
29:e1-8, 2004
47. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Hase R, Takahashi R,
Mega S, Shichinohe T, Kawarada Y, Itoh T, Okushiba S, Kondo S, Katoh H.: Expression of pigment
epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients
with ductal pancreatic adenocarcinoma. Cancer Res 64:3533-3537, 2004
48. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M,
Aozasa K, Kawase I, Hayashi N, Monden M.: Hepatoma-derived growth factor is a novel prognostic
factor for patients with pancreatic cancer. Clin Cancer Res 12:6043-6048, 2006
49. Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, Seifert JK, Adwan H, Berger MR,
Junginger T, Galle PR, Moehler M.: Strong expression of chemokine receptor CXCR4 by pancreatic
cancer correlates with advanced disease. Oncol Rep 16:1159-1164, 2006
